Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis.

Pelechas E, Voulgari PV, Drosos AA.

Ther Clin Risk Manag. 2019 Sep 4;15:1073-1079. doi: 10.2147/TCRM.S167452. eCollection 2019.

2.

Reply to the Editor.

Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA.

Semin Arthritis Rheum. 2019 Aug 1. pii: S0049-0172(19)30477-9. doi: 10.1016/j.semarthrit.2019.07.005. [Epub ahead of print] No abstract available.

PMID:
31466838
3.

Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: real-world data from a university centre registry.

Papadopoulos CG, Gartzonikas IK, Pappa TK, Markatseli TE, Migkos MP, Voulgari PV, Drosos AA.

Rheumatol Adv Pract. 2019 Mar 14;3(1):rkz007. doi: 10.1093/rap/rkz007. eCollection 2019.

4.

Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?

Drosos AA, Pelechas E, Voulgari PV.

J Clin Med. 2019 Aug 16;8(8). pii: E1237. doi: 10.3390/jcm8081237.

5.

Maintained Clinical Remission in Ankylosing Spondylitis Patients Switched from Reference Infliximab to Its Biosimilar: An 18-Month Comparative Open-Label Study.

Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA.

J Clin Med. 2019 Jul 2;8(7). pii: E956. doi: 10.3390/jcm8070956.

6.

B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis.

Antonopoulos I, Daoussis D, Lalioti ME, Markatseli TE, Drosos AA, Taraviras S, Andonopoulos AP, Liossis SC.

Rheumatol Int. 2019 Nov;39(11):1889-1898. doi: 10.1007/s00296-019-04350-4. Epub 2019 Jun 21.

PMID:
31227855
7.

Cochlear involvement in patients with systemic autoimmune rheumatic diseases: a clinical and laboratory comparative study.

Tsirves GK, Voulgari PV, Pelechas E, Asimakopoulos AD, Drosos AA.

Eur Arch Otorhinolaryngol. 2019 Sep;276(9):2419-2426. doi: 10.1007/s00405-019-05487-5. Epub 2019 May 30.

PMID:
31175453
8.

Comment on: Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.

Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA.

Rheumatology (Oxford). 2019 Oct 1;58(10):1883-1884. doi: 10.1093/rheumatology/kez206. No abstract available.

PMID:
31170297
9.

Conventional radiography of the hands and wrists in rheumatoid arthritis. What a rheumatologist should know and how to interpret the radiological findings.

Drosos AA, Pelechas E, Voulgari PV.

Rheumatol Int. 2019 Aug;39(8):1331-1341. doi: 10.1007/s00296-019-04326-4. Epub 2019 May 22. Review.

PMID:
31119369
10.

The impact of temporal artery biopsy for the diagnosis of giant cell arteritis in clinical practice in a tertiary university hospital.

Kaltsonoudis E, Pelechas E, Papoudou-Bai A, Markatseli TE, Elisaf M, Voulgari PV, Drosos AA.

PLoS One. 2019 Mar 29;14(3):e0210845. doi: 10.1371/journal.pone.0210845. eCollection 2019.

11.

Golimumab for Rheumatoid Arthritis.

Pelechas E, Voulgari PV, Drosos AA.

J Clin Med. 2019 Mar 20;8(3). pii: E387. doi: 10.3390/jcm8030387. Review.

12.

Unmet needs in the treatment of ankylosing spondylitis: a long-term observational study from a single university center.

Pelechas E, Kaltsonoudis E, Voulgari PV, Drosos AA.

Rheumatol Int. 2019 Apr;39(4):663-668. doi: 10.1007/s00296-019-04277-w. Epub 2019 Mar 15.

PMID:
30877371
13.

Etanercept biosimilar SB-4.

Pelechas E, Drosos AA.

Expert Opin Biol Ther. 2019 Mar;19(3):173-179. doi: 10.1080/14712598.2019.1566456. Epub 2019 Jan 11. Review.

PMID:
30616405
14.

Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review.

Pelechas E, Papoudou-Bai A, Voulgari PV, Drosos AA.

Rheumatol Int. 2019 Feb;39(2):353-357. doi: 10.1007/s00296-018-4212-0. Epub 2018 Dec 7. Review.

PMID:
30523477
15.

Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study.

Panopoulos S, Tektonidou M, Drosos AA, Liossis SN, Dimitroulas T, Garyfallos A, Sakkas L, Boumpas D, Voulgari PV, Daoussis D, Thomas K, Georgiopoulos G, Vosvotekas G, Vassilopoulos D, Sfikakis PP.

Arthritis Res Ther. 2018 Dec 4;20(1):267. doi: 10.1186/s13075-018-1771-0.

16.

Epidemiological characteristics of psoriatic arthritis.

Migkos MP, Somarakis GP, Markatseli TE, Voulgari PV, Drosos AA.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):324-332. Epub 2018 Oct 8. Review.

PMID:
30299245
17.

Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center.

Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA.

Semin Arthritis Rheum. 2019 Feb;48(4):597-602. doi: 10.1016/j.semarthrit.2018.06.003. Epub 2018 Jun 22.

PMID:
30075990
18.

An Extensive Study of the Functional Polymorphisms of Kinin-Kallikrein System in Rheumatoid Arthritis Susceptibility.

Chatzikyriakidou A, Voulgari PV, Drosos AA.

Arch Rheumatol. 2017 Sep 13;33(1):33-38. doi: 10.5606/ArchRheumatol.2018.6389. eCollection 2018 Mar.

19.

Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.

Flouri ID, Markatseli TE, Boki KA, Papadopoulos I, Skopouli FN, Voulgari PV, Settas L, Zisopoulos D, Iliopoulos A, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P.

J Rheumatol. 2018 Jun;45(6):785-794. doi: 10.3899/jrheum.170477. Epub 2018 Apr 1.

20.

ABP 501 for the treatment of rheumatoid arthritis.

Pelechas E, Voulgari PV, Drosos AA.

Expert Opin Biol Ther. 2018 Mar;18(3):317-322. doi: 10.1080/14712598.2018.1430760. Epub 2018 Jan 24. Review.

PMID:
29350566
21.

High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.

Thomas K, Flouri I, Repa A, Fragiadaki K, Sfikakis PP, Koutsianas C, Kaltsonoudis E, Voulgari PV, Drosos AA, Petrikkou E, Sidiropoulos P, Vassilopoulos D.

Clin Exp Rheumatol. 2018 Mar-Apr;36(2):254-262. Epub 2017 Nov 9.

PMID:
29148406
22.

Hydroxychloroquine-induced dark butterfly rash in a rheumatoid arthritis patient.

Pelechas E, Drosos AA.

Rheumatology (Oxford). 2017 Oct 23. doi: 10.1093/rheumatology/kex388. [Epub ahead of print] No abstract available.

PMID:
29088445
23.

A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor.

Pelechas E, Memi T, Voulgari PV, Drosos AA.

Rheumatol Ther. 2017 Dec;4(2):509-513. doi: 10.1007/s40744-017-0084-0. Epub 2017 Oct 11.

24.

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management.

Giacomelli R, Afeltra A, Alunno A, Baldini C, Bartoloni-Bocci E, Berardicurti O, Carubbi F, Cauli A, Cervera R, Ciccia F, Cipriani P, Conti F, De Vita S, Di Benedetto P, Doria A, Drosos AA, Favalli EG, Gandolfo S, Gatto M, Grembiale RD, Liakouli V, Lories R, Lubrano E, Lunardi C, Margiotta DPE, Massaro L, Meroni P, Minniti A, Navarini L, Pendolino M, Perosa F, Pers JO, Prete M, Priori R, Puppo F, Quartuccio L, Ruffatti A, Ruscitti P, Russo B, Sarzi-Puttini P, Shoenfeld Y, Somarakis GA, Spinelli FR, Tinazzi E, Triolo G, Ursini F, Valentini G, Valesini G, Vettori S, Vitali C, Tzioufas AG.

Autoimmun Rev. 2017 Sep;16(9):911-924. doi: 10.1016/j.autrev.2017.07.012. Epub 2017 Jul 11. Review.

PMID:
28705780
25.

Uncommon presentation of granulomatosis with polyangiitis in association with subclinical coeliac disease.

Voulgari PV, Apostolou F, Dounousi E, Liapis G, Elisaf M, Drosos AA.

Clin Exp Rheumatol. 2018 Mar-Apr;36 Suppl 111(2):160. Epub 2017 Jun 9. No abstract available.

PMID:
28598778
26.

Intercentre variance in patient reported outcomes is lower than objective rheumatoid arthritis activity measures: a cross-sectional study.

Khan NA, Spencer HJ, Nikiphorou E, Naranjo A, Alten R, Chirieac RM, Drosos AA, Géher P, Inanc N, Kerzberg E, Ancuta CM, Müller R, Ørnbjerg L, Sokka T.

Rheumatology (Oxford). 2017 Aug 1;56(8):1395-1400. doi: 10.1093/rheumatology/kex076.

PMID:
28575509
27.

Sirukumab: a promising therapy for rheumatoid arthritis.

Pelechas E, Voulgari PV, Drosos AA.

Expert Opin Biol Ther. 2017 Jun;17(6):755-763. doi: 10.1080/14712598.2017.1315099. Epub 2017 Apr 10.

PMID:
28374627
28.

Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.

Sfikakis PP, Bournia VK, Sidiropoulos P, Boumpas DT, Drosos AA, Kitas GD, Konstantonis G, Liossis SN, Manoussakis MN, Sakkas L, Tektonidou M, Tzioufas AG, Vlachoyiannopoulos PG, Kani C, Paterakis P, Litsa P, Vassilopoulos D.

Clin Exp Rheumatol. 2017 Jul-Aug;35(4):579-585. Epub 2017 Mar 3.

PMID:
28281458
29.

Transfusion-related acute lung injury in a patient with systemic lupus erythematosus.

Pelechas E, Gerolymatou N, Voulgari PV, Drosos AA.

Clin Exp Rheumatol. 2017 Mar-Apr;35(2):353. Epub 2017 Jan 27. No abstract available.

PMID:
28134082
30.

A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.

Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, Georgiou P, Andonopoulos AP, Drosos AA, Sakkas L, Liossis SN.

Semin Arthritis Rheum. 2017 Apr;46(5):625-631. doi: 10.1016/j.semarthrit.2016.10.003. Epub 2016 Oct 13.

PMID:
27839742
31.

Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status.

Boubouchairopoulou N, Flouri I, Drosos AA, Boki K, Settas L, Zisopoulos D, Skopouli FN, Papadopoulos I, Iliopoulos A, Kyriopoulos J, Boumpas DT, Athanasakis K, Sidiropoulos P.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):999-1005. Epub 2016 Oct 7.

PMID:
27749220
32.

Impaired Antiatherogenic Functions of High-density Lipoprotein in Patients with Ankylosing Spondylitis.

Gkolfinopoulou C, Stratikos E, Theofilatos D, Kardassis D, Voulgari PV, Drosos AA, Chroni A.

J Rheumatol. 2015 Sep;42(9):1652-60. doi: 10.3899/jrheum.141532. Epub 2015 Aug 1.

PMID:
26233507
33.

Tuberculous pyomyositis in a rheumatoid arthritis patient treated with anakinra.

Migkos MP, Somarakis GA, Markatseli TE, Matthaiou M, Kosta P, Voulgari PV, Drosos AA.

Clin Exp Rheumatol. 2015 Sep-Oct;33(5):734-6. Epub 2015 May 1.

PMID:
25936426
34.

Counting Costs under Severe Financial Constraints: A Cost-of-Illness Analysis of Spondyloarthropathies in a Tertiary Hospital in Greece.

Tsifetaki N, Migkos MP, Papagoras C, Voulgari PV, Athanasakis K, Drosos AA.

J Rheumatol. 2015 Jun;42(6):963-7. doi: 10.3899/jrheum.141277. Epub 2015 Apr 1.

PMID:
25834213
35.

Lower PHQ-9 cutpoint accurately diagnosed depression in people with long-term conditions attending the Accident and Emergency Department.

Hyphantis T, Kotsis K, Kroenke K, Paika V, Constantopoulos S, Drosos AA, Carvalho AF, Guthrie E; ARISTEIA-ABREVIATE Study Group members.

J Affect Disord. 2015 May 1;176:155-63. doi: 10.1016/j.jad.2015.01.062. Epub 2015 Feb 7.

PMID:
25721612
36.

Golimumab, the newest TNF-α blocker, comes of age.

Papagoras C, Voulgari PV, Drosos AA.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4):570-7. Epub 2015 Jan 20. Review.

PMID:
25602858
37.

Painless shoulder mass.

Nikas S, Drosos AA.

Joint Bone Spine. 2015 Jul;82(4):286. doi: 10.1016/j.jbspin.2014.09.001. Epub 2015 Jan 2. No abstract available.

PMID:
25559764
38.

Evidence of ERBB3 gene association with rheumatoid arthritis predisposition.

Chatzikyriakidou A, Voulgari PV, Drosos AA.

Int J Rheum Dis. 2016 Feb;19(2):146-9. doi: 10.1111/1756-185X.12514. Epub 2014 Dec 20.

PMID:
25530448
39.

Cancer diagnosis in a cohort of patients with Sjogren's syndrome and rheumatoid arthritis: a single-center experience and review of the literature.

Boussios S, Pentheroudakis G, Somarakis G, Markatseli TE, Drosos AA, Pavlidis N.

Anticancer Res. 2014 Nov;34(11):6669-76.

PMID:
25368273
40.

The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program.

Grøn KL, Ornbjerg LM, Hetland ML, Aslam F, Khan NA, Jacobs JW, Henrohn D, Rasker JJ, Kauppi MJ, Lang HC, Mota LM, Aggarwal A, Yamanaka H, Badsha H, Gossec L, Cutolo M, Ferraccioli G, Gremese E, Bong Lee E, Inanc N, Direskeneli H, Taylor P, Huisman M, Alten R, Pohl C, Oyoo O, Stropuviene S, Drosos AA, Kerzberg E, Ancuta C, Mofti A, Bergman M, Detert J, Selim ZI, Abda EA, Rexhepi B, Sokka T.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):869-77. Epub 2014 Oct 20.

PMID:
25327997
41.

Sense of coherence and self-sacrificing defense style as predictors of psychological distress and quality of life in rheumatoid arthritis: a 5-year prospective study.

Goulia P, Voulgari PV, Tsifetaki N, Andreoulakis E, Drosos AA, Carvalho AF, Hyphantis T.

Rheumatol Int. 2015 Apr;35(4):691-700. doi: 10.1007/s00296-014-3134-8. Epub 2014 Sep 21.

PMID:
25240430
42.

Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review.

Kotsis K, Voulgari PV, Drosos AA, Carvalho AF, Hyphantis T.

Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):857-72. doi: 10.1586/14737167.2014.957679. Epub 2014 Sep 5. Review.

PMID:
25193010
43.

Non-HLA genes in ankylosing spondylitis: what meta-analyses have shown?

Chatzikyriakidou A, Voulgari PV, Drosos AA.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5):735-9. Epub 2014 Jul 28. Review.

PMID:
25068597
44.

Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study.

Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA.

Arthritis Res Ther. 2014 Jun 17;16(3):R125. doi: 10.1186/ar4582.

45.

Lack of association of the GSDMB gene at locus 17q12 with predisposition to rheumatoid arthritis.

Chatzikyriakidou A, Voulgari PV, Drosos AA.

Clin Exp Rheumatol. 2014 May-Jun;32(3):447. Epub 2014 May 21. No abstract available.

PMID:
24848122
46.

Heart involvement in systemic sclerosis: a combined echocardiographic and scintigraphic study.

Papagoras C, Achenbach K, Tsifetaki N, Tsiouris S, Fotopoulos A, Drosos AA.

Clin Rheumatol. 2014 Aug;33(8):1105-11. doi: 10.1007/s10067-014-2666-3. Epub 2014 May 22.

PMID:
24847773
47.

Illness perceptions and psychological distress associated with physical health-related quality of life in primary Sjögren's syndrome compared to systemic lupus erythematosus and rheumatoid arthritis.

Kotsis K, Voulgari PV, Tsifetaki N, Drosos AA, Carvalho AF, Hyphantis T.

Rheumatol Int. 2014 Dec;34(12):1671-81. doi: 10.1007/s00296-014-3008-0. Epub 2014 Apr 27.

PMID:
24769916
48.

Effect of hydroxychloroquine on the lipid profile of patients with Sjögren syndrome.

Migkos MP, Markatseli TE, Iliou C, Voulgari PV, Drosos AA.

J Rheumatol. 2014 May;41(5):902-8. doi: 10.3899/jrheum.131156. Epub 2014 Mar 15.

PMID:
24634203
49.

Adalimumab in the treatment of rheumatoid arthritis.

Voulgari PV, Drosos AA.

Expert Opin Biol Ther. 2014 Mar 4. [Epub ahead of print]

PMID:
24588123
50.

Certolizumab for rheumatoid arthritis.

Markatseli TE, Papagoras C, Nikoli A, Voulgari PV, Drosos AA.

Clin Exp Rheumatol. 2014 May-Jun;32(3):415-23. Epub 2014 Jan 20. Review.

PMID:
24447441

Supplemental Content

Loading ...
Support Center